Anti-tumour necrosis factor therapy associated with cutaneous vasculitis

Abstract
Sir, We read with interest the letter by McCain et al. [1] and we wish to add our experience of a case of probable vasculitis or cutaneous reaction secondary to anti‐tumour necrosis factor (anti‐TNF) therapy, as has been noted by others. While injection site reactions can occur in up to 20% of patients receiving etanercept [2], more generalized reactions are only recently being recognized [1, 3–6].

This publication has 0 references indexed in Scilit: